{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:39Z","timestamp":1792839699687,"version":"4.5.0"},"reference-count":70,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Prior to the Food and Drug Administration approval of ledipaspavir\/sofosbuvir (Harvoni\u00ae) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin. This treatment had low cure rates for hepatitis C virus and was teratogenic and therefore avoided in pregnant patients. Vertical transmission is the most common transmission of hepatitis C in pediatric patients, whereas medical equipment that was not properly cleaned and sterilized, blood products which were not checked (historically), sharing and reusing syringes and needles, and dialysis are the most common forms of hepatitis C transmission in adults. The treatment of pregnant women with direct-acting antivirals is important because the treatment of pediatric patients cannot begin until three years of age and does not always occur prior to the symptom development of hepatitis C. This review article will include glecaprevir\/pibrentasvir (Mayvret\u00ae), sofosbuvir\/velpatasvir (Epclusa\u00ae), and sofosbuvir\/velpatasvir plus voxilaprevir (Vosevi\u00ae). We aim to review the teratogenic risk of direct-acting antivirals as well as currently published clinical trials and ongoing research on direct-acting antiviral hepatitis C treatment in pregnancy in this publication.<\/jats:p>","DOI":"10.3390\/pathogens13060508","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:48:31Z","timestamp":1718614111000},"page":"508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Direct-Acting Antiviral Agents in Prevention of Maternal\u2013Fetal Transmission of Hepatitis C Virus in Pregnancy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-387X","authenticated-orcid":false,"given":"Christopher","family":"Hartley","sequence":"first","affiliation":[{"name":"The Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5209-6687","authenticated-orcid":false,"given":"Trung","family":"Van","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-5459","authenticated-orcid":false,"given":"Wikrom","family":"Karnsakul","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,16]]},"reference":[{"key":"ref_1","unstructured":"Hepatitis, C. (2023, November 19). World Health Organization Web Site. Updated 2023. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2014","journal-title":"Hepatology"},{"key":"ref_3","unstructured":"(2024, January 02). Number of Newly Reported Chronic Hepatitis C Virus Infection Cases by Sex and Age\u2014United States. Updated 2023, Available online: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c\/figure-3.8.htm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2017.07.039","article-title":"Hepatitis C in pregnancy: Screening, treatment, and management","volume":"217","author":"Hughes","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dibba, P., Cholankeril, R., Li, A.A., Patel, M., Fayek, M., Dibble, C., Okpara, N., Hines, A., and Ahmed, A. (2018). Hepatitis C in pregnancy. Diseases, 6.","DOI":"10.3390\/diseases6020031"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e4777","DOI":"10.1097\/MD.0000000000004777","article-title":"Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38.e1","DOI":"10.1016\/j.ajog.2008.03.052","article-title":"Pregnancy complications associated with hepatitis C: Data from a 2003\u20132005 washington state birth cohort","volume":"199","author":"Pergam","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1478-3231.2011.02556.x","article-title":"Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes","volume":"31","author":"Connell","year":"2011","journal-title":"Liver Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.3748\/wjg.v19.i40.6714","article-title":"Hepatitis C and pregnancy","volume":"19","author":"Floreani","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S914","DOI":"10.1016\/S0168-8278(23)02939-2","article-title":"Burden of hepatitis C in pregnant women and children in the United States","volume":"78","author":"Wasuwanich","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/430601","article-title":"Three broad modalities in the natural history of vertically acquired hepatitis C virus infection","volume":"41","author":"Network","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1086\/345908","article-title":"Chronic Hepatitis C Virus Infection in Childhood: Clinical Patterns and Evolution in 224 White Children","volume":"36","author":"Jara","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-term course of chronic hepatitis C in children: From Viral Clearance to End-Stage Liver Disease","volume":"134","author":"Bortolotti","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","article-title":"Epidemiology and natural history of hepatitis C virus infection among children and young people","volume":"70","author":"Modin","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.mpg.0000228117.52229.32","article-title":"Hepatitis C in children: A quaternary referral center perspective","volume":"43","author":"Rumbo","year":"2006","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/QAD.0b013e3282703810","article-title":"HCV\/HIV co-infection, HCV viral load and mode of delivery: Risk factors for mother-to-child transmission of hepatitis C virus?","volume":"21","author":"Giordanengo","year":"2007","journal-title":"AIDS"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/515668","article-title":"Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women","volume":"178","author":"Papaevangelou","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1086\/430949","article-title":"Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV\/HCV-coinfected persons","volume":"192","author":"Blackard","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/infdis\/166.6.1276","article-title":"Hepatitis C virus is detected in a monocyte\/macrophage subpopulation of peripheral blood mononuclear cells of infected patients","volume":"166","author":"Bouffard","year":"1992","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0897.2010.00836.x","article-title":"The immune system in pregnancy: A unique complexity","volume":"63","author":"Mor","year":"2010","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0889-8545(05)70346-6","article-title":"Immunology of HIV and pregnancy. The effects of each on the other","volume":"24","author":"Landers","year":"1997","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/v4123531","article-title":"Pathogenesis of Hepatitis C during Pregnancy and Childhood","volume":"4","author":"Larouche","year":"2012","journal-title":"Viruses"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0033-1334459","article-title":"Hepatitis C virus in pregnancy","volume":"30","author":"Honegger","year":"2013","journal-title":"Am. J. Perinatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0168-8278(99)80031-2","article-title":"Detection of hepatitis C virus RNA (HCV RNA) in amniotic fluid: A prospective study","volume":"31","author":"Delamare","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/plac.2000.0579","article-title":"Phenotype of the endothelium in the Human Term Placenta","volume":"22","author":"Dye","year":"2001","journal-title":"Placenta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2007.05.002","article-title":"Influence of maternal lipid profile on placental protein expression of LDLr and SR-BI","volume":"359","author":"Duchesne","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4254\/wjh.v6.i8.538","article-title":"Vertical hepatitis C virus transmission: Main questions and answers","volume":"6","author":"Tosone","year":"2014","journal-title":"World J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.14218\/JCTH.2016.00067","article-title":"Mechanisms and prevention of vertical transmission in chronic viral hepatitis","volume":"5","author":"Mavilia","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"European Paediatric Hepatitis C Virus Network (2001). Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. european paediatric hepatitis C virus network. BJOG, 108, 371\u2013377.","DOI":"10.1111\/j.1471-0528.2001.00088.x"},{"key":"ref_30","unstructured":"Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention (2024, June 12). Center for Disease Control and Prevention Web Site. Updated 2020, Available online: https:\/\/www.cdc.gov\/hepatitis\/policy\/npr\/2020\/NationalProgressReport-HepC-ReduceInfections.htm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/jvh.12430","article-title":"Chronic hepatitis C virus infection is associated with increased risk of preterm birth: A meta-analysis of observational studies","volume":"22","author":"Huang","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1111\/j.1365-2893.2011.01436.x","article-title":"Pregnancy outcomes associated with viral hepatitis","volume":"18","author":"Reddick","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clinre.2016.07.004","article-title":"Hepatitis C infection and intrahepatic cholestasis of pregnancy: A systematic review and meta-analysis","volume":"41","author":"Wijarnpreecha","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e024288","DOI":"10.1136\/bmjopen-2018-024288","article-title":"Hepatitis C and pregnancy outcomes: A systematic review protocol","volume":"8","author":"Parent","year":"2018","journal-title":"BMJ Open"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jarasvaraparn, C., Hartley, C., and Karnsakul, W. (2024). Updated clinical guidelines and management of hepatitis C infection in children. Pathogens, 13.","DOI":"10.3390\/pathogens13020180"},{"key":"ref_36","unstructured":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C (2024, June 12). The American Association for the Study of Liver Diseases and The Infectious Diseases Society of America Web Site. Updated 2022. Available online: https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/AASLD-IDSA_HCVGuidance_October_24_2022.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/bdr2.2094","article-title":"Final results from the ribavirin pregnancy registry, 2004\u20132020","volume":"114","author":"Sinclair","year":"2022","journal-title":"Birth Defects Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2125.2006.02704.x","article-title":"Pharmacokinetics of ribavirin in patients with hepatitis C virus","volume":"62","author":"Wade","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.26519","article-title":"Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: A retrospective study","volume":"58","author":"Mohan","year":"2013","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/nm.3351","article-title":"Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses","volume":"19","author":"Honegger","year":"2013","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1074-7613(00)80044-8","article-title":"Analysis of a successful immune response against hepatitis C virus","volume":"10","author":"Cooper","year":"1999","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.chom.2023.05.018","article-title":"SINE RNA of the imprinted miRNA clusters mediates constitutive type III interferon expression and antiviral protection in hemochorial placentas","volume":"31","author":"Wickramage","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_44","unstructured":"Glecaprevir\/Pibrentasvir (Mayvret) (2024, June 12). Access Data FDA: AbbVie, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_45","unstructured":"Sofosbuvir\/Velpatasvir (Epclusa) (2024, June 12). Access Data FDA: Gilead Sciences, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_46","unstructured":"Sofosbuvir\/Velpatasvir Plus Voxilaprevir (Vosevi) (2024, June 12). Access Data FDA: Gilead Sciences, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_47","unstructured":"Ledipasvir\/Sofosbuvir (Harvoni) (2024, June 12). Access Data FDA: Gilead Sciences, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_48","unstructured":"FDA Pregnancy Categories (2023, November 26). US Department of Health and Human Services Chemical Hazards Emergency Medical Management Web Site. Updated 2023, Available online: https:\/\/chemm.hhs.gov\/pregnancycategories.htm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2468-1253(22)00168-6","article-title":"Hepatitis C in pregnancy and the TiP-HepC registry","volume":"7","author":"Gupta","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_50","unstructured":"List of pregnancy exposure registries (2023, November 26). Food and Drug Administration Office of Women\u2019s Health Web Site. Updated 2023. Available online: https:\/\/www-fda-gov.proxy1.library.jhu.edu\/science-research\/womens-health-research\/list-pregnancy-exposure-registries."},{"key":"ref_51","first-page":"B8","article-title":"Society for maternal-fetal medicine consult series #56: Hepatitis C in pregnancy-updated guidelines: Replaces con-sult number 43, november 2017","volume":"225","author":"Kuller","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00404-010-1588-9","article-title":"Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+\/HIV\u2212 mothers: A meta-analysis","volume":"283","author":"Chehreh","year":"2010","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.15476","article-title":"Review article: Direct-acting antivirals for the treatment of HCV during pregnancy and lactation-implications for maternal dosing, foetal exposure, and safety for mother and child","volume":"50","author":"Freriksen","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study","volume":"1","author":"Scarsi","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/S0618-8278(19)30412-8","article-title":"THU-137-DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome","volume":"70","author":"Elakel","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_56","first-page":"S292","article-title":"Treatment of chronic hepatitis C with ledipasvir\/sofosbuvir combination during pregnancy","volume":"12","author":"Yattoo","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.placenta.2018.07.005","article-title":"Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications","volume":"69","author":"Pfeifer","year":"2018","journal-title":"Placenta"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s005350170056","article-title":"Gastric emptying and orocecal transit time in pregnancy","volume":"36","author":"Chiloiro","year":"2001","journal-title":"J. Gastroenterol."},{"key":"ref_60","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","article-title":"Pharmacokinetics of drugs in pregnancy","volume":"39","author":"Feghali","year":"2015","journal-title":"Semin. Perinatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab. Rev."},{"key":"ref_64","first-page":"743","article-title":"Drug-induced nephrotoxicity","volume":"78","author":"Naughton","year":"2008","journal-title":"Am. Fam. Physician"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/0003-4819-158-2-201301150-00575","article-title":"Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. preventive services task force","volume":"158","author":"Cottrell","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4254\/wjh.v8.i12.557","article-title":"Antiviral therapy for hepatitis C: Has anything changed for pregnant\/lactating women?","volume":"8","author":"Spera","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_67","unstructured":"(2023, November 26). The Treatment in Pregnancy for Hepatitis C (TiP-HepC) Registry. Clinical Trials.gov Web Site. Updated 2022, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05368974?cond=Hepatitis%20C&term=Pregnancy&intr=Direct%20Acting%20Antivirals&rank=1."},{"key":"ref_68","unstructured":"(2023, November 26). Treatment of Chronic Hepatitis C during Pregnancy with Sofosbuvir\/Velpatasvir. Clinical Trials.gov Web Site. Updated 2023, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04382404."},{"key":"ref_69","unstructured":"Chappell, C., Charles, J., Smid, M., Rood, K., and Hiller, S. (2023, January 10\u201314). Safety, tolerability, and outcomes of sofosbuvir\/velpatasvir in treatment of chronic hepatitis C virus during pregnancy. Proceedings of the AASLD Conference, Boston, MA, USA."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wasuwanich, P., So, J.M., Presnell, B., Karnsakul, W., Egerman, R.S., and Wen, T.S. (2024). Composite score for predicting vertical transmission of hepatitis C: A multicenter study. Pathogens, 13.","DOI":"10.3390\/pathogens13010045"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:59:36Z","timestamp":1760108376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,16]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["pathogens13060508"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13060508","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,16]]}}}